News articles about Charles River Laboratories (NYSE:CRL) have trended somewhat positive on Friday, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Charles River Laboratories earned a coverage optimism score of 0.10 on Accern’s scale. Accern also assigned news stories about the medical research company an impact score of 46.1815570942899 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the media headlines that may have effected Accern’s rankings:
- National Research (NRCIB) & Charles River Laboratories (CRL) Head-To-Head Contrast (americanbankingnews.com)
- Charles River Laboratories (CRL) Rating Reiterated by Barclays (americanbankingnews.com)
- $481.32 Million in Sales Expected for Charles River Laboratories (CRL) This Quarter (americanbankingnews.com)
- Charles River Laboratories (CRL) Rating Lowered to Buy at BidaskClub (americanbankingnews.com)
- Zacks: Brokerages Anticipate Charles River Laboratories (CRL) Will Post Earnings of $1.26 Per Share (americanbankingnews.com)
Shares of CRL opened at $106.00 on Friday. Charles River Laboratories has a 52-week low of $86.66 and a 52-week high of $119.05. The company has a market capitalization of $5,128.02, a price-to-earnings ratio of 20.48, a price-to-earnings-growth ratio of 1.62 and a beta of 0.68. The company has a current ratio of 1.78, a quick ratio of 1.54 and a debt-to-equity ratio of 1.06.
Charles River Laboratories (NYSE:CRL) last issued its quarterly earnings results on Tuesday, February 13th. The medical research company reported $1.40 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.26 by $0.14. Charles River Laboratories had a return on equity of 26.14% and a net margin of 6.64%. The business had revenue of $478.50 million during the quarter, compared to the consensus estimate of $475.02 million. During the same period in the previous year, the business earned $1.21 EPS. The business’s quarterly revenue was up 2.5% on a year-over-year basis. sell-side analysts expect that Charles River Laboratories will post 5.77 earnings per share for the current fiscal year.
A number of research firms have commented on CRL. TheStreet downgraded Charles River Laboratories from an “a-” rating to a “c+” rating in a report on Tuesday, February 13th. ValuEngine cut Charles River Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, April 7th. JPMorgan Chase raised their price target on Charles River Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a research report on Wednesday, February 14th. SunTrust Banks upgraded Charles River Laboratories from a “hold” rating to a “buy” rating and lifted their price target for the company from $107.66 to $125.00 in a report on Wednesday, February 14th. Finally, Royal Bank of Canada set a $116.00 price target on Charles River Laboratories and gave the company a “hold” rating in a report on Tuesday, February 13th. Eight investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $116.85.
In related news, CEO James C. Foster sold 4,800 shares of the company’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $106.69, for a total transaction of $512,112.00. Following the completion of the transaction, the chief executive officer now directly owns 306,914 shares in the company, valued at approximately $32,744,654.66. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director George M. Milne, Jr. sold 7,740 shares of the company’s stock in a transaction on Friday, March 9th. The stock was sold at an average price of $115.00, for a total value of $890,100.00. Following the transaction, the director now owns 36,760 shares of the company’s stock, valued at $4,227,400. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 62,658 shares of company stock valued at $6,875,393. 2.10% of the stock is owned by company insiders.
ILLEGAL ACTIVITY WARNING: “Charles River Laboratories (CRL) Earns Daily News Sentiment Rating of 0.10” was originally posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.thelincolnianonline.com/2018/04/20/charles-river-laboratories-crl-receives-coverage-optimism-rating-of-0-10.html.
About Charles River Laboratories
Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).
Receive News & Ratings for Charles River Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.